Celldex Therapeutics Inc
Celldex Therapeutics Inc (CLDX) Option Chain
Read more
Tracking the CLDX option chain helps you see every strike and expiry on Celldex Therapeutics Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of CLDX options activity at a glance. Use our scanner to monitor the CLDX option chain in real time and filter for the trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For CLDX stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where CLDX options are being actively traded, and where they are not.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 49.26 | 62 | 2 | -0.27 | 1.92 | 1.35 | 1.95 | 28.00 | -0.96 | 0.85 | 1.85 | 0.00 | 1.35 | 0 | 1 | 50.74 |
| 59.74 | 114 | 2 | 0.33 | 0.92 | 1.00 | 1.50 | 29.00 | +2.58 | 1.50 | 2.00 | 0.00 | 1.75 | 0 | 30 | 40.26 |
| 69.25 | 156 | 39 | 0.88 | 0.00 | 0.65 | 1.10 | 30.00 | +6.12 | 0.40 | 3.40 | 0.08 | 1.82 | 0 | 1,113 | 30.75 |
| 77.36 | 23 | 0 | 0.53 | 0.00 | 0.30 | 0.75 | 31.00 | +9.66 | 1.55 | 4.90 | 1.08 | 2.15 | 0 | 145 | 22.64 |
| 83.91 | 21 | 0 | 0.53 | 0.00 | 0.05 | 1.00 | 32.00 | +13.19 | 1.50 | 5.80 | 2.08 | 1.57 | 0 | 140 | 16.09 |
As of Nov 5, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank39.68% Moderate
- Market cap (M$)2,220
- 52 weeks high-37.37%
- 52 weeks low27.92%
- Analyst recommendationStrong Buy
1.20 - Target price$63.07
110.82% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-09
- P/E—
- Future P/E—
- EPS (ttm)-4.36
- EPS growth next 5 years4.36%
As of Nov 5, 2026